PRESS RELEASEParis, June 5th 2025 Aive raises 12 million euros to become the world's leaderin automated video post-production Paris, June 5th 2025 – Video post-production automation platform Aive raises €12 million in Series A funding, led by international investment firm Invus. This round of financing, which comes just over a year after the launch of…
DUBAI, United Arab Emirates, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or “the Company”), a global shared intelligent electric mobility ecosystem company headquartered in California, announced today that the Company hosted a Co-Creation Delivery Ceremony in the UAE for FX Super One’s first global owner and…
VANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) is pleased to report that all nine drillholes of the 2025 Huckleberry mine diamond drilling program, totalling 1,743 metres, intersected copper, molybdenum, silver, and gold mineralization. Drillhole MZ-25-1 intersected an elevated gold interval of 22.6 metres of 0.23…
TORRANCE, Calif., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) and the Asian distribution giant WT Microelectronics Co., Ltd. (TW: 3036) have strengthened their strategic partnership to provide enhanced technical and supply chain services of the leading Gallium Nitride…
Press release - Paris, November 27th, 2025 Update on shareholding structureShare sale project SMCP was informed today of the initiation of a process to sell SMCP shares representing up to 51.2% of its share capital. This process will be managed by Lazard Frères. The affected SMCP shares include:
Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about PD-L1 x 4-1BB (CD137) Bispecific Antibodies provides an up-to-date competitor evaluation in the field of emerging therapy candidates in research and development targeting simultaneously PD-L1 and 4-1BB…
